Cargando…
Precision medicine in pediatric oncology
PURPOSE OF REVIEW: The current review describes recent advances and unique challenges in precision medicine for pediatric cancers and highlights clinical trials assessing the clinical impact of targeted therapy matched to molecular alterations identified by tumor profiling. RECENT FINDINGS: Multiple...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams and Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770114/ https://www.ncbi.nlm.nih.gov/pubmed/29189430 http://dx.doi.org/10.1097/MOP.0000000000000570 |
_version_ | 1783293024870072320 |
---|---|
author | Forrest, Suzanne J. Geoerger, Birgit Janeway, Katherine A. |
author_facet | Forrest, Suzanne J. Geoerger, Birgit Janeway, Katherine A. |
author_sort | Forrest, Suzanne J. |
collection | PubMed |
description | PURPOSE OF REVIEW: The current review describes recent advances and unique challenges in precision medicine for pediatric cancers and highlights clinical trials assessing the clinical impact of targeted therapy matched to molecular alterations identified by tumor profiling. RECENT FINDINGS: Multiple prospective clinical sequencing studies in pediatric oncology have been reported in the last 2 years. These studies demonstrated feasibility of sequencing in the clinic and revealed a rate of actionable variants that justifies the development of precision trials for childhood cancer. A number of precision medicine trials are recently completed, underway or in development and these will be reviewed herein, with a focus on highlighting aspects of precision medicine trial design relevant to pediatric oncology. SUMMARY: The primary results of the first round of pediatric precision oncology clinical trials will provide us with a greater understanding of the clinical impact of linking tumor profiling to selection of targeted therapies. The aggregation of sequencing and clinical data from these trials and the results of biologic investigations linked to these trials will drive further discoveries and broaden opportunities for precision medicine for children with cancer. |
format | Online Article Text |
id | pubmed-5770114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams and Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-57701142018-02-02 Precision medicine in pediatric oncology Forrest, Suzanne J. Geoerger, Birgit Janeway, Katherine A. Curr Opin Pediatr HEMATOLOGY AND ONCOLOGY: Edited by Susan M. Blaney PURPOSE OF REVIEW: The current review describes recent advances and unique challenges in precision medicine for pediatric cancers and highlights clinical trials assessing the clinical impact of targeted therapy matched to molecular alterations identified by tumor profiling. RECENT FINDINGS: Multiple prospective clinical sequencing studies in pediatric oncology have been reported in the last 2 years. These studies demonstrated feasibility of sequencing in the clinic and revealed a rate of actionable variants that justifies the development of precision trials for childhood cancer. A number of precision medicine trials are recently completed, underway or in development and these will be reviewed herein, with a focus on highlighting aspects of precision medicine trial design relevant to pediatric oncology. SUMMARY: The primary results of the first round of pediatric precision oncology clinical trials will provide us with a greater understanding of the clinical impact of linking tumor profiling to selection of targeted therapies. The aggregation of sequencing and clinical data from these trials and the results of biologic investigations linked to these trials will drive further discoveries and broaden opportunities for precision medicine for children with cancer. Lippincott Williams and Wilkins 2018-02 2017-12-14 /pmc/articles/PMC5770114/ /pubmed/29189430 http://dx.doi.org/10.1097/MOP.0000000000000570 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | HEMATOLOGY AND ONCOLOGY: Edited by Susan M. Blaney Forrest, Suzanne J. Geoerger, Birgit Janeway, Katherine A. Precision medicine in pediatric oncology |
title | Precision medicine in pediatric oncology |
title_full | Precision medicine in pediatric oncology |
title_fullStr | Precision medicine in pediatric oncology |
title_full_unstemmed | Precision medicine in pediatric oncology |
title_short | Precision medicine in pediatric oncology |
title_sort | precision medicine in pediatric oncology |
topic | HEMATOLOGY AND ONCOLOGY: Edited by Susan M. Blaney |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770114/ https://www.ncbi.nlm.nih.gov/pubmed/29189430 http://dx.doi.org/10.1097/MOP.0000000000000570 |
work_keys_str_mv | AT forrestsuzannej precisionmedicineinpediatriconcology AT geoergerbirgit precisionmedicineinpediatriconcology AT janewaykatherinea precisionmedicineinpediatriconcology |